Michael R. Waterfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael R. Waterfield has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Jun Hyung Sin
Biomedical Sciences Graduate Program, University of California , San Francisco
8 shared publications - Sloan H. Phillips
Department of Pediatrics, University of California, San Francisco, San Francisco, USA
7 shared publications - Sujit Kashyap
Department of Genetics University of Delhi South Campus New Delhi India
7 shared publications - Jacqueline L. Yee
University of California San Francisco 2 Biomedical Sciences Graduate Program San Francisco, California
6 shared publications - Matthew H. Spitzer
University of California, San Francisco
6 shared publications - Maya Lopez-Ichikawa
University of California San Francisco 2 Biomedical Sciences Graduate Program San Francisco, California
6 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 4 - GSEA reveals increased IL-2 and IL-7 signaling with Atf7ipdeficiency.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 4 - GSEA reveals increased IL-2 and IL-7 signaling with Atf7ipdeficiency.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 6 – ATF7IP expression overlaps with IL7R and HAVCR2 in breast cancer.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 6 – ATF7IP expression overlaps with IL7R and HAVCR2 in breast cancer.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 2 – ATF7ip inhibits the immune response to MC38.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 2 – ATF7ip inhibits the immune response to MC38.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 5 – Marker genes in P14+ scRNA-seq.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
Supplementary Fig. 5 – Marker genes in P14+ scRNA-seq.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
CD8+ T-cell exhaustion limits the immune response to tumors because of ineffective T-cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. In this study, we identified activating transcription factor 7–interacting protein (ATF7ip) as an epigenetic protein critical for inducing T-cell exhaustion. Loss of Atf7ip in CD8+ T cells resulted in decreased terminal exhaustion and increased numbers of progenitor-exhausted cells in both chronic viral infections and cancer. Given the decreased T-cell terminal exhaustion observed with Atf7ip deficiency in CD8+ T cells, this may be one mechanism that leads to decreased tumor burden. Mechanistically, ATF7ip functions to stimulate the deposition of repressive H3K9me3 at critical immune-effector gene loci, such as Il7r and Il2, leading to enhanced exhaustion. Our data suggest that ATF7ip may be a rational target for deletion in adoptive T-cell therapies to reduce CD8+ T-cell exhaustion.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
CD8+ T-cell exhaustion limits the immune response to tumors because of ineffective T-cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. In this study, we identified activating transcription factor 7–interacting protein (ATF7ip) as an epigenetic protein critical for inducing T-cell exhaustion. Loss of Atf7ip in CD8+ T cells resulted in decreased terminal exhaustion and increased numbers of progenitor-exhausted cells in both chronic viral infections and cancer. Given the decreased T-cell terminal exhaustion observed with Atf7ip deficiency in CD8+ T cells, this may be one mechanism that leads to decreased tumor burden. Mechanistically, ATF7ip functions to stimulate the deposition of repressive H3K9me3 at critical immune-effector gene loci, such as Il7r and Il2, leading to enhanced exhaustion. Our data suggest that ATF7ip may be a rational target for deletion in adoptive T-cell therapies to reduce CD8+ T-cell exhaustion.
- 25 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (7) , 1462-1475
Thymic alveolar type 2 epithelial mimetic cells revealed by RUNX1 deficiency
Autoimmune diseases can affect the lungs, and the mechanisms used to prevent autoimmune lung disease are incompletely understood. Recent studies in the thymus have identified unique populations of medullary thymic epithelial cells (mTECs) called mimetic cells that transcriptionally mimic peripheral epithelial populations. These mimetic cells have important functions in the thymus in immune tolerance. Here, we used a mouse line with thymic-specific deletion of Runt-related transcription factor 1 (Runx1) to identify a new mimetic cell akin to alveolar type 2 (AT2) lung epithelial cells. AT2 mTECs express surfactant genes, and with Runx1 deletion AT2 mTECs expand, resulting in a loss of AIRE+ mTECs and defects in T cell selection. RUNX1 suppresses AT2 mTECs by inhibiting epidermal growth factor receptor signaling. Together, our results identify a thymic mimetic cell type that mimics lung AT2 epithelial cells, further uncovering unrealized epithelial diversity in the thymus.
- 25 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (7) , 1462-1475
Thymic alveolar type 2 epithelial mimetic cells revealed by RUNX1 deficiency
Autoimmune diseases can affect the lungs, and the mechanisms used to prevent autoimmune lung disease are incompletely understood. Recent studies in the thymus have identified unique populations of medullary thymic epithelial cells (mTECs) called mimetic cells that transcriptionally mimic peripheral epithelial populations. These mimetic cells have important functions in the thymus in immune tolerance. Here, we used a mouse line with thymic-specific deletion of Runt-related transcription factor 1 (Runx1) to identify a new mimetic cell akin to alveolar type 2 (AT2) lung epithelial cells. AT2 mTECs express surfactant genes, and with Runx1 deletion AT2 mTECs expand, resulting in a loss of AIRE+ mTECs and defects in T cell selection. RUNX1 suppresses AT2 mTECs by inhibiting epidermal growth factor receptor signaling. Together, our results identify a thymic mimetic cell type that mimics lung AT2 epithelial cells, further uncovering unrealized epithelial diversity in the thymus.
- 15 May 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 161, 103573
Runx3 instructs Aire+ mTEC development, TSA gene expression, and central tolerance
- 15 May 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 161, 103573
Runx3 instructs Aire+ mTEC development, TSA gene expression, and central tolerance
- 13 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , 1054-1067
ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
CD8+ T-cell exhaustion limits the immune response to tumors because of ineffective T-cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. In this study, we identified activating transcription factor 7–interacting protein (ATF7ip) as an epigenetic protein critical for inducing T-cell exhaustion. Loss of Atf7ip in CD8+ T cells resulted in decreased terminal exhaustion and increased numbers of progenitor-exhausted cells in both chronic viral infections and cancer. Given the decreased T-cell terminal exhaustion observed with Atf7ip deficiency in CD8+ T cells, this may be one mechanism that leads to decreased tumor burden. Mechanistically, ATF7ip functions to stimulate the deposition of repressive H3K9me3 at critical immune-effector gene loci, such as Il7r and Il2, leading to enhanced exhaustion. Our data suggest that ATF7ip may be a rational target for deletion in adoptive T-cell therapies to reduce CD8+ T-cell exhaustion.
- 13 April 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , 1054-1067
ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion
CD8+ T-cell exhaustion limits the immune response to tumors because of ineffective T-cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. In this study, we identified activating transcription factor 7–interacting protein (ATF7ip) as an epigenetic protein critical for inducing T-cell exhaustion. Loss of Atf7ip in CD8+ T cells resulted in decreased terminal exhaustion and increased numbers of progenitor-exhausted cells in both chronic viral infections and cancer. Given the decreased T-cell terminal exhaustion observed with Atf7ip deficiency in CD8+ T cells, this may be one mechanism that leads to decreased tumor burden. Mechanistically, ATF7ip functions to stimulate the deposition of repressive H3K9me3 at critical immune-effector gene loci, such as Il7r and Il2, leading to enhanced exhaustion. Our data suggest that ATF7ip may be a rational target for deletion in adoptive T-cell therapies to reduce CD8+ T-cell exhaustion.
- Open Access
- 10 February 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (2) , e1011489
A machine learning classifier to identify and prioritise genes associated with murine cardiac development
Congenital heart disease (CHD) is a major cause of infant mortality and presents life-long challenges to individuals living with these conditions. Genetic causes are known for only a minority of types of CHD. Discovering further genetic causes is limited by challenges in prioritising candidate genes. We examined a wide range of features of mouse genes, including sequence characteristics, protein localisation and interaction data, developmental expression data and gene ontology annotations. Many features differ between genes needed for cardiac development and non-cardiac genes, suggesting that these two gene types can be distinguished by their attributes. We therefore developed a supervised machine learning (ML) method to identify Mus musculus genes with a high probability of being involved in cardiac development. These genes, when mutated, are candidates for causing human CHD. Our classifier showed a cross-validation accuracy of 81% in detecting cardiac and non-cardiac genes. From our classifier we generated predictions of the cardiac development association status for all protein-coding genes in the mouse genome. We also cross-referenced our predictions with datasets of known human CHD genes, determining which are orthologues of predicted mouse cardiac genes. Our predicted cardiac genes have a high overlap with human CHD genes. Thus, our predictions could inform the prioritisation of genes when evaluating CHD patient sequence data for genetic diagnosis. Knowledge of cardiac developmental genes may speed up reaching a genetic diagnosis for patients born with CHD.
- 10 February 2026
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 22 (2) , e1011489
Open AccessA machine learning classifier to identify and prioritise genes associated with murine cardiac development
Congenital heart disease (CHD) is a major cause of infant mortality and presents life-long challenges to individuals living with these conditions. Genetic causes are known for only a minority of types of CHD. Discovering further genetic causes is limited by challenges in prioritising candidate genes. We examined a wide range of features of mouse genes, including sequence characteristics, protein localisation and interaction data, developmental expression data and gene ontology annotations. Many features differ between genes needed for cardiac development and non-cardiac genes, suggesting that these two gene types can be distinguished by their attributes. We therefore developed a supervised machine learning (ML) method to identify Mus musculus genes with a high probability of being involved in cardiac development. These genes, when mutated, are candidates for causing human CHD. Our classifier showed a cross-validation accuracy of 81% in detecting cardiac and non-cardiac genes. From our classifier we generated predictions of the cardiac development association status for all protein-coding genes in the mouse genome. We also cross-referenced our predictions with datasets of known human CHD genes, determining which are orthologues of predicted mouse cardiac genes. Our predicted cardiac genes have a high overlap with human CHD genes. Thus, our predictions could inform the prioritisation of genes when evaluating CHD patient sequence data for genetic diagnosis. Knowledge of cardiac developmental genes may speed up reaching a genetic diagnosis for patients born with CHD.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (88) , eabq3109
Ikaros is a principal regulator of Aire + mTEC homeostasis, thymic mimetic cell diversity, and central tolerance
Mutations in the gene encoding the zinc-finger transcription factor Ikaros ( IKZF1 ) are found in patients with immunodeficiency, leukemia, and autoimmunity. Although Ikaros has a well-established function in modulating gene expression programs important for hematopoietic development, its role in other cell types is less well defined. Here, we uncover functions for Ikaros in thymic epithelial lineage development in mice and show that Ikzf1 expression in medullary thymic epithelial cells (mTECs) is required for both autoimmune regulator–positive (Aire + ) mTEC development and tissue-specific antigen (TSA) gene expression. Accordingly, TEC-specific deletion of Ikzf1 in mice results in a profound decrease in Aire + mTECs, a global loss of TSA gene expression, and the development of autoimmunity. Moreover, Ikaros shapes thymic mimetic cell diversity, and its deletion results in a marked expansion of thymic tuft cells and muscle-like mTECs and a loss of other Aire-dependent mimetic populations. Single-cell analysis reveals that Ikaros modulates core transcriptional programs in TECs that correlate with the observed cellular changes. Our findings highlight a previously undescribed role for Ikaros in regulating epithelial lineage development and function and suggest that failed thymic central tolerance could contribute to the autoimmunity seen in humans with IKZF1 mutations.
- 27 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (88) , eabq3109
Ikaros is a principal regulator of Aire + mTEC homeostasis, thymic mimetic cell diversity, and central tolerance
Mutations in the gene encoding the zinc-finger transcription factor Ikaros ( IKZF1 ) are found in patients with immunodeficiency, leukemia, and autoimmunity. Although Ikaros has a well-established function in modulating gene expression programs important for hematopoietic development, its role in other cell types is less well defined. Here, we uncover functions for Ikaros in thymic epithelial lineage development in mice and show that Ikzf1 expression in medullary thymic epithelial cells (mTECs) is required for both autoimmune regulator–positive (Aire + ) mTEC development and tissue-specific antigen (TSA) gene expression. Accordingly, TEC-specific deletion of Ikzf1 in mice results in a profound decrease in Aire + mTECs, a global loss of TSA gene expression, and the development of autoimmunity. Moreover, Ikaros shapes thymic mimetic cell diversity, and its deletion results in a marked expansion of thymic tuft cells and muscle-like mTECs and a loss of other Aire-dependent mimetic populations. Single-cell analysis reveals that Ikaros modulates core transcriptional programs in TECs that correlate with the observed cellular changes. Our findings highlight a previously undescribed role for Ikaros in regulating epithelial lineage development and function and suggest that failed thymic central tolerance could contribute to the autoimmunity seen in humans with IKZF1 mutations.